文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

危险相关细胞外ATP削弱MDSC在急性GVHD中的治疗疗效

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.
PubMed 文献 · Blood · 2019-01-01

该研究在小鼠急性移植物抗宿主病(GVHD)模型中发现,预处理方案诱导的细胞外ATP通过P2x7R激活NLRP3炎症小体,导致供体髓源性抑制细胞(MDSC)分化并丧失抑制功能。P2x7R或NLRP3敲除的供体MDSC显著提高生存率,而全身性抑制炎症小体或降低IL-1β可能有害;限制于MDSC的炎症小体激活缺失或腹腔给予三磷酸腺苷双磷酸酶(apyrase)可增强MDSC疗效。

要点

  • 预处理释放的ATP通过P2x7R-NLRP3轴驱动MDSC功能障碍。
  • P2x7R或NLRP3敲除的供体MDSC比野生型显著提高生存率。
  • MDSC来源的IL-1β信号对最佳抑制功能是必需的。

核心结论

  • 细胞外ATP通过P2x7R和NLRP3炎症小体激活导致供体MDSC功能障碍,限制其在急性GVHD中的疗效。
  • MDSC限制性而非全身性抑制炎症小体或IL-1β信号可改善生存,而全身性抑制可能有害。

研究设计与样本

  • 小鼠急性GVHD模型,比较野生型与P2x7R敲除、NLRP3敲除或IL-1β敲除的供体MDSC输注效果。
  • 使用药理学抑制剂、apyrase腹腔给药、调节性T细胞输注及新型炎症小体报告菌株评估炎症小体激活。

主要发现

  • P2x7R或NLRP3敲除的供体MDSC提供显著高于野生型MDSC的生存率。
  • 体内药理学靶向NLRP3或P2x7R促进受体生存,但与MDSC联合未见协同生存优势。
  • IL-1β敲除供体MDSC相对野生型MDSC效果更差,而外源性IL-1β增加MDSC抑制 potency。
  • 腹腔给予apyrase与野生型MDSC协同,调节性T细胞输注减少但未消除MDSC炎症小体激活。

临床怎么用

  • 未来临床使用MDSC降低炎症环境中的同种免疫反应时,应考虑限制MDSC内炎症小体激活而非全身性抑制。
  • 围移植期腹腔给予apyrase或联合调节性T细胞可能增强MDSC疗法疗效。

局限性

  • 研究仅基于小鼠急性GVHD模型,结果外推至临床需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloid-derived suppressor cells (MDSCs) can subdue inflammation. In mice with acute graft-versus-host disease (GVHD), donor MDSC infusion enhances survival that is only partial and transient because of MDSC inflammasome activation early posttransfer, resulting in differentiation and loss of suppressor function. Here we demonstrate that conditioning regimen-induced adenosine triphosphate (ATP) release is a primary driver of MDSC dysfunction through ATP receptor (P2x7R) engagement and NLR pyrin family domain 3 (NLRP3) inflammasome activation. P2x7R or NLRP3 knockout (KO) donor MDSCs provided significantly higher survival than wild-type (WT) MDSCs. Although in vivo pharmacologic targeting of NLRP3 or P2x7R promoted recipient survival, indicating in vivo biologic effects, no synergistic survival advantage was seen when combined with MDSCs. Because activated inflammasomes release mature interleukin-1β (IL-1β), we expected that IL-1β KO donor MDSCs would be superior in subverting GVHD, but such MDSCs proved inferior relative to WT. IL-1β release and IL-1 receptor expression was required for optimal MDSC function, and exogenous IL-1β added to suppression assays that included MDSCs increased suppressor potency. These data indicate that prolonged systemic NLRP3 inflammasome inhibition and decreased IL-1β could diminish survival in GVHD. However, loss of inflammasome activation and IL-1β release restricted to MDSCs rather than systemic inhibition allowed non-MDSC IL-1β signaling, improving survival. Extracellular ATP catalysis with peritransplant apyrase administered into the peritoneum, the ATP release site, synergized with WT MDSCs, as did regulatory T-cell infusion, which we showed reduced but did not eliminate MDSC inflammasome activation, as assessed with a novel inflammasome reporter strain. These findings will inform future clinical using MDSCs to decrease alloresponses in inflammatory environments.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Koehn BH, Saha A, McDonald-Hyman C, et al. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. Blood. 2019. PMID: 31533918. doi:10.1182/blood.2019001950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。